Details for New Drug Application (NDA): 213239
✉ Email this page to a colleague
NDA 213239 describes DEFERIPRONE, which is a drug marketed by Hikma and Taro and is included in two NDAs. It is available from two suppliers. Additional details are available on the DEFERIPRONE profile page.
The generic ingredient in DEFERIPRONE is deferiprone. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferiprone profile page.
The generic ingredient in DEFERIPRONE is deferiprone. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferiprone profile page.
Summary for 213239
| Tradename: | DEFERIPRONE |
| Applicant: | Hikma |
| Ingredient: | deferiprone |
| Patents: | 0 |
Pharmacology for NDA: 213239
| Mechanism of Action | Iron Chelating Activity |
Suppliers and Packaging for NDA: 213239
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DEFERIPRONE | deferiprone | TABLET;ORAL | 213239 | ANDA | Hikma Pharmaceuticals USA Inc. | 0054-0576 | 0054-0576-25 | 100 TABLET, COATED in 1 BOTTLE (0054-0576-25) |
| DEFERIPRONE | deferiprone | TABLET;ORAL | 213239 | ANDA | Hikma Pharmaceuticals USA Inc. | 0054-0711 | 0054-0711-19 | 50 TABLET, COATED in 1 BOTTLE (0054-0711-19) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Mar 29, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 1GM | ||||
| Approval Date: | Feb 8, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
